Article Text

Download PDFPDF
Implantable defibrillators in hypertrophic cardiomyopathy
  1. Andrew Grace1,2
  1. 1
    Department of Cardiology, Papworth Hospital, Cambridge, UK
  2. 2
    Division of Cardiovascular Biology, School of Biological Sciences, University of Cambridge, Cambridge, UK
  1. Dr Andrew Grace, Papworth Hospital and University of Cambridge, Cambridge CB23 3RE, UK; ag{at}bioc.cam.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The implantable defibrillator (ICD) is one of the transformational technologies defining contemporary procedural cardiology. Advances in all aspects of device design have facilitated implantation and the detection, discrimination and correction of rhythms that otherwise can result in death.1 2 However, as with most advanced technologies, initial enthusiasm is tempered by experience, which in the case of ICDs has highlighted the leads as a major source of mischief.3 As emphasised in numerous articles, these highly engineered components, while generally withstanding the battering of the intravascular environment, can on occasion fail.4 Lead design has evolved, but failure with potential consequences of inappropriate shocks, the need for revision and possible death have softened the enthusiasm of referrers. The upside is that ICDs are extremely effective and provide almost complete protection against sudden cardiac death (SCD). The difficulties remain in balancing the benefits weighed in relation to the largely technical but very real potential risks of devices. Of course, the longer the device is in place, the greater both the potential benefit and the incremental risks,4 so in the younger patient the heavier the burden when deciding between options.

One disease that highlights the difficulty of these decisions is hypertrophic cardiomyopathy (HCM). This is by almost an order of magnitude more common than other diseases associated with SCD in the young and is likely to be seen in general cardiology practice. The literature …

View Full Text

Footnotes

  • Competing interests: Cameron Health Inc. (Consultant, Clinical Advisory Board); Medtronic Inc. (Research Support).

Linked Articles